Wirth Peter

Director at SYRS; Director at ZLAB; Director at Forma Therapeutics Holdings, Inc.,, and 1 more

Sold, on record
$18.5M
Dollars the filings state
Form 4 sales
5
Latest Dec 8, 2022
Form 144 notices
1
Proposed sales
Quarters with a sale
0 of the last 8
No sale in two years
Companies
4
Filed as an executive or holder

Companies

Sales by reason

0
Routine
1
Plan not stated
0
No plan
4
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per year, every sale on record.

Sales chart range

Sales by company

Shares sold, every Form 4 sale on record.

Timeline

  1. Mar 11, 2025Notice

    SYRS

    Filed a notice to sell 9,333 shares

    $2k9,333 shares

    Filed Mar 11, 2025Form 144

  2. Dec 8, 2022Plan not stated

    ZLAB

    Sold 2.2% of their holdings

    $278k7,852 shares at $35.35

    Filed Dec 9, 2022Form 4

  3. Jun 23, 2020Unusual

    Forma Therapeutics Holdings, Inc.,

    Sold 100% of their holdings

    78,454 shares

    Filed Jun 24, 2020Form 4

  4. May 25, 2010Unusual

    GENZYME CORP

    Sold 30.5% of their holdings

    $304k6,665 shares at $45.62

    Filed May 26, 2010Form 4

  5. May 17, 2010Unusual

    GENZYME CORP

    Sold 87.6% of their holdings

    $2.4M48,216 shares at $50.51

    Filed May 19, 2010Form 4

  6. Jan 16, 2009Unusual

    GENZYME CORP

    Sold 97.5% of their holdings

    $15.4M232,180 shares at $66.50

    Filed Jan 20, 2009Form 4

6 of 6

Every transaction

Every transaction on a Form 4 or Form 5 by Wirth Peter
TradedFiledStockRoleWhatAmountPriceValueHeld afterSource
Jun 17, 2026Jun 22, 2026ZLABDirectorAwarded22,371416,121SEC
Jun 18, 2025Jun 23, 2025ZLABDirectorAwarded10,831393,750SEC
Jun 18, 2024Jun 20, 2024ZLABDirectorAwarded21,253382,919SEC
Jun 5, 2024Jun 7, 2024SYRSDirectorAwardedStock Option (right to buy)6,0006,000SEC
Jun 5, 2024Jun 7, 2024SYRSDirectorAwarded4,00016,000SEC
Jun 29, 2023Jun 30, 2023ZLABDirectorAwarded18,903$26.45$500k361,666SEC
Jun 1, 2023Jun 2, 2023SYRSDirectorAwardedStock Option (right to buy)6,0006,000SEC
Jun 1, 2023Jun 2, 2023SYRSDirectorAwarded4,00012,000SEC
Dec 8, 2022Dec 9, 2022ZLABDirectorSold7,852$35.35$278k0SEC
Oct 14, 2022Oct 14, 2022Forma Therapeutics Holdings, Inc.,DirectorTendered134,9150SEC
Oct 14, 2022Oct 14, 2022Forma Therapeutics Holdings, Inc.,DirectorReturned to the companyStock Option (Right to Buy)74,7370SEC
Sep 16, 2022Sep 19, 2022SYRSDirectorAwardedStock Option (right to buy)12,00012,000SEC
Sep 16, 2022Sep 19, 2022SYRSDirectorAwarded8,0008,000SEC
Jun 8, 2022Jun 9, 2022Forma Therapeutics Holdings, Inc.,DirectorAwardedStock Option (Right to Buy)6,7506,750SEC
Jun 8, 2022Jun 9, 2022Forma Therapeutics Holdings, Inc.,DirectorAwarded4,500134,915SEC
Jun 1, 2022Jun 2, 2022SYRSDirectorAwardedStock Option (right to buy)17,50017,500SEC
Jan 3, 2022Jan 4, 2022ZLABDirectorAwarded7,763350,615SEC
Dec 8, 2021Dec 8, 2021ZLABDirectorBought4,000$71.36$285k342,852SEC
Jun 17, 2021Jun 21, 2021Forma Therapeutics Holdings, Inc.,DirectorAwardedStock Option (Right to Buy)8,3758,375SEC
Jun 17, 2021Jun 21, 2021Forma Therapeutics Holdings, Inc.,DirectorAwarded2,750130,415SEC
Jun 8, 2021Jun 10, 2021SYRSDirectorAwardedStock Option (right to buy)17,50017,500SEC
Jan 15, 2021Jan 20, 2021ZLABDirectorAwarded3,852338,852SEC
Jun 23, 2020Jun 24, 2020Forma Therapeutics Holdings, Inc.,DirectorSold78,4540SEC
Jun 23, 2020Jun 24, 2020Forma Therapeutics Holdings, Inc.,DirectorBought63,299127,665SEC
Jun 18, 2020Jun 22, 2020Forma Therapeutics Holdings, Inc.,DirectorAwardedStock Option (Right to Buy)17,5330SEC
Jun 11, 2020Jun 11, 2020SYRSDirectorAwardedStock Option (right to buy)17,50017,500SEC
Jun 11, 2019Jun 12, 2019SYRSDirectorAwardedStock Option (right to buy)11,00011,000SEC
Jun 14, 2018Jun 15, 2018SYRSDirectorAwardedStock Option (right to buy)11,00011,000SEC
Jan 27, 2017Jan 30, 2017SYRSDirectorAwardedStock Option (Right to Buy)22,00022,000SEC
Jun 22, 2015Jun 23, 2015TRIMERIS INCDirectorReturned to the companyStock Options (Right to Buy)30,0000SEC
Jun 4, 2014Jun 5, 2014TRIMERIS INCDirectorAwardedStock Option (Right to Buy)7,5007,500SEC
Jun 6, 2013Jun 10, 2013TRIMERIS INCDirectorAwardedStock Option (Right to Buy)7,5007,500SEC
Jun 27, 2012Jun 29, 2012TRIMERIS INCDirectorAwardedStock Option (Right to Buy)15,00015,000SEC
Apr 4, 2011Apr 6, 2011GENZYME CORPExec VP,Legal & Corporate Dev.Tendered15,808$74.00$1.2M0SEC
Apr 4, 2011Apr 6, 2011GENZYME CORPExec VP,Legal & Corporate Dev.Exercised or settledRestricted Stock Units29,2500SEC
Apr 4, 2011Apr 6, 2011GENZYME CORPExec VP,Legal & Corporate Dev.Exercised options29,25044,910SEC
Apr 4, 2011Apr 6, 2011GENZYME CORPExec VP,Legal & Corporate Dev.Returned to the companyStock Option (right to buy)734,045$49.21$36.1M0SEC
Apr 4, 2011Apr 6, 2011GENZYME CORPExec VP,Legal & Corporate Dev.Returned to the company29,250$74.00$2.2M0SEC
Jun 16, 2010Jun 18, 2010GENZYME CORPExec VP,Legal & Corporate Dev.AwardedStock Option (right to buy)42,750$51.52$2.2M42,750SEC
May 25, 2010May 26, 2010GENZYME CORPExec VP,Legal & Corporate Dev.Sold6,665$45.62$304k15,191SEC
May 24, 2010May 26, 2010GENZYME CORPExec VP,Legal & Corporate Dev.Exercised or settledRestricted Stock Units15,0000SEC
May 24, 2010May 26, 2010GENZYME CORPExec VP,Legal & Corporate Dev.Exercised options15,00021,856SEC
May 17, 2010May 19, 2010GENZYME CORPExec VP,Legal & Corporate Dev.Sold48,216$50.51$2.4M6,856SEC
May 17, 2010May 19, 2010GENZYME CORPExec VP,Legal & Corporate Dev.Exercised or settledStock Option (right to buy)48,216$26.50$1.3M0SEC
May 17, 2010May 19, 2010GENZYME CORPExec VP,Legal & Corporate Dev.Exercised options48,216$26.50$1.3M55,072SEC
May 21, 2009May 26, 2009GENZYME CORPExec VP,Legal & Corporate Dev.AwardedRestricted Stock Units57,00042,750SEC
Jan 16, 2009Jan 20, 2009GENZYME CORPExec VP,Legal & Corporate Dev.Sold232,180$66.50$15.4M6,068SEC
Jan 16, 2009Jan 20, 2009GENZYME CORPExec VP,Legal & Corporate Dev.Exercised or settledGenzyme NQ stock option (right to buy)232,1800SEC
Jan 16, 2009Jan 20, 2009GENZYME CORPExec VP,Legal & Corporate Dev.Exercised options232,180$29.44$6.8M238,248SEC
May 22, 2008May 27, 2008GENZYME CORPExecutive Vice PresidentAwardedGenzyme NQ Stock Option (right to buy)60,00015,000SEC
Page 1

Sales and notices (6)

Form 144 notices and Form 4 sales by Wirth Peter
Source
Mar 11, 2025Mar 11, 2025SYRSDirectorForm 144 notice9,333$2kNoticeSEC
Dec 8, 2022Dec 9, 2022ZLABDirectorForm 4 sale7,852$278k2.2%Plan not statedSEC
Jun 23, 2020Jun 24, 2020Forma Therapeutics Holdings, Inc.,DirectorForm 4 sale78,454100.0%UnusualSEC
May 25, 2010May 26, 2010GENZYME CORPExec VP,Legal & Corporate Dev.Form 4 sale6,665$304k30.5%UnusualSEC
May 17, 2010May 19, 2010GENZYME CORPExec VP,Legal & Corporate Dev.Form 4 sale48,216$2.4M87.6%UnusualSEC
Jan 16, 2009Jan 20, 2009GENZYME CORPExec VP,Legal & Corporate Dev.Form 4 sale232,180$15.4M97.5%UnusualSEC